Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

Table 7 Terminal measurements after systemic in vivo pravastatin treatment

Week 12	CKD ( n = 6)	CKD + pravastatin ( n = 5)
Body weight (g)	357 ± 24	369 ± 16
Heart weight (g/100 g BW)	0.45 ± 0.02	0.42 ± 0.03*
Kidney weight (g/100 g BW)	0.57 ± 0.02	0.57 ± 0.04
MAP (mmHg)	168 ± 19	164 ± 19
GFR (μl/minute/100 g)	340 ± 60	332 ± 41
ERPF(μl/minute/100 g)	1335 ± 291	1221 ± 189
Hematocrit	0.41 ± 0.02	0.40 ± 0.02
FF (%)	28 ± 3	26 ± 2
Cholesterol (mmol/l)	2.89 ± 0.53	2.73 ± 0.46
Triglycerides (mmol/l)	1.42 ± 0.38	0.70 ± 0.37*
Fold change hepatic HMGCR mRNA expression	1.000 ± 0.56	1.584 ± 0.65

Data presented as mean ± standard deviation. BW, body weight; CKD, chronic kidney disease; ERPF, effective renal plasma flow; FF, filtration fraction; GFR, glomerular filtration rate; HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; MAP, mean arterial pressure. *P <0.05 compared with CKD.

ISSN: 1757-6512